We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 2.98 | 1.85% | 163.79 | 164.25 | 160.74 | 161.85 | 5,850,104 | 01:00:00 |
From Nov 2023 to May 2024
By Ben Glickman
CVS Health's pharmacy benefit management unit will add Humira biosimilars to its covered drug lists starting April 1.
The Woonsocket, R.I.-based pharmacy and healthcare giant said Wednesday that the AbbVie-made autoimmune-disease treatment Humira would be removed from CVS Caremark's national commercial template formularies, or the lists which determine prescription drug coverage by health plans.
The company said Humira would still be an option for customers with Choice and Standard Opt Out commercial formularies.
Biosimilars are drugs and treatment with no clinically meaningful difference from branded alternatives.
CVS said that AbbVie had agreed to supply a committed volume of co-branded Humira to CVS subsidiary Cordavis. The business was launched in August with a focus on making biosimilar products.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 03, 2024 17:44 ET (22:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
